Advertisement

Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim

Published:October 07, 2022DOI:https://doi.org/10.1016/j.transci.2022.103582

      Abstract

      Immune-mediated platelet transfusion refractoriness due to anti-human leukocyte antigen (HLA) antibodies can occur in approximately 9% of patients with myelodysplastic syndromes (MDS) and can lead to an increased risk of clinically relevant bleeds and treatment delays. These patients are typically managed with frequent platelet transfusions; however, HLA-matched platelet transfusions are usually available only in large blood centers. For this reason, alloimunized thrombocytopenic MDS patients are notoriously difficult to manage. Here, we present a case of a MDS patient with an immune-mediated platelet transfusion refractoriness, severe thrombocytopenia and spontaneous subarachnoid hemorhage who we successfully treated with romiplostim, a thrombopoietin receptor agonist.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Transfusion and Apheresis Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Al Ameri A.
        • Jabbour E.
        • Garcia-Manero G.
        • O'Brien S.
        • Faderl S.
        • Ravandi F.
        • et al.
        Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications.
        Clin Lymphoma Myeloma Leuk. 2011; 11: 237-241
        • Doll D.C.
        • List A.F.
        Myelodysplastic syndromes.
        West J Med. 1989; 151: 161-167
        • Cohn C.S.
        Platelet transfusion refractoriness: how do I diagnose and manage?.
        Hematol Am Soc Hematol Educ Program. 2020; 2020: 527-532
        • Cheok K.P.L.
        • Chhetri R.
        • Wee L.Y.A.
        • Friel O.
        • Pham A.
        • Salvi A.
        • et al.
        The burden of immune-mediated refractoriness to platelet transfusions in myelodysplastic syndromes.
        Transfusion. 2020; 60: 2192-2198
        • Komrokji R.S.
        • Kulasekararaj A.
        • Al Ali N.H.
        • Kordasti S.
        • Bart-Smith E.
        • Craig B.M.
        • et al.
        Autoimmune diseases and myelodysplastic syndromes.
        Am J Hematol. 2016; 91: E280-3
        • Meng F.
        • Chen X.
        • Yu S.
        • Ren X.
        • Liu Z.
        • Fu R.
        • et al.
        Safety and efficacy of eltrombopag and romiplostim in myelodysplastic syndromes: a systematic review and meta-analysis.
        Front Oncol. 2020; 10582686
        • Mittelman M.
        • Oster H.S.
        Thrombocytopenia in myelodysplastic syndromes: time to lift the embargo on thrombomimetics?.
        Br J Haematol. 2021; 194: 231-233
        • van Dijk W.E.M.
        • Brandwijk O.N.
        • Heitink-Polle K.M.J.
        • Schutgens R.E.G.
        • van Galen K.P.M.
        • Urbanus R.T.
        Hemostatic changes by thrombopoietin-receptor agonists in immune thrombocytopenia patients.
        Blood Rev. 2021; 47100774
        • Vrbensky J.R.
        • Moore J.E.
        • Arnold D.M.
        • Smith J.W.
        • Kelton J.G.
        • Nazy I.
        The sensitivity and specificity of platelet autoantibody testing in immune thrombocytopenia: a systematic review and meta-analysis of a diagnostic test.
        J Thromb Haemost. 2019; 17: 787-794
        • Oliva E.N.
        • Alati C.
        • Santini V.
        • Poloni A.
        • Molteni A.
        • Niscola P.
        • et al.
        Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
        Lancet Haematol. 2017; 4: e127-e136
        • Vicente A.
        • Patel B.A.
        • Gutierrez-Rodrigues F.
        • Groarke E.
        • Giudice V.
        • Lotter J.
        • et al.
        Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome.
        Haematologica. 2020; 105: 2785-2794